SRR35579846
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.500
- ALLOGRAFT_REJECTION+0.490
- INTERFERON_GAMMA_RESPONSE+0.470
- COMPLEMENT+0.370
- IL6_JAK_STAT3_SIGNALING+0.350
- INFLAMMATORY_RESPONSE+0.280
- HEME_METABOLISM+0.180
- BILE_ACID_METABOLISM+0.160
- PROTEIN_SECRETION+0.160
- APOPTOSIS+0.140
Top 10 suppressed
- MYC_TARGETS_V2-0.530
- PANCREAS_BETA_CELLS-0.390
- HYPOXIA-0.350
- MYC_TARGETS_V1-0.340
- OXIDATIVE_PHOSPHORYLATION-0.300
- ADIPOGENESIS-0.270
- GLYCOLYSIS-0.240
- CHOLESTEROL_HOMEOSTASIS-0.230
- WNT_BETA_CATENIN_SIGNALING-0.230
- TGF_BETA_SIGNALING-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-02920 | — | cohortA1 | 0.813 |
| 2 | SRR25043622 | — | — | 0.810 |
| 3 | SRR2932840 | — | — | 0.809 |
| 4 | TCGA-62-A46U-01A-11R-A24H-07 | — | cohortA1 | 0.801 |
| 5 | ERR2208965 | — | — | 0.795 |
| 6 | 2d12ea90-c4f4-4aca-b353-360057b446e2 | — | — | 0.793 |
| 7 | TCGA-44-3919-01A-02R-1107-07 | — | cohortA1 | 0.791 |
| 8 | be8d8236-4ebc-46de-a4fd-a901fec1cdce | — | — | 0.787 |
| 9 | TCGA-86-6851-01A-11R-1949-07 | — | cohortA1 | 0.782 |
| 10 | TCGA-86-7954-01A-11R-2187-07 | — | cohortA1 | 0.775 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.490 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.180 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.160 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.140 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.110 | Idelalisib | — uncovered |
| COAGULATION | 0.090 | Binimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.070 | Inavolisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.040 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.030 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.020 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.020 | Idelalisib | — uncovered |